Vanguard Reports 0% Stake in Korro Bio
Korro Bio Inc — The Vanguard Group filed an amendment to a Schedule 13G/A stating it beneficially owns 0 shares of Korro Bio common stock, representing 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Korro Bio Inc — The Vanguard Group filed an amendment to a Schedule 13G/A stating it beneficially owns 0 shares of Korro Bio common stock, representing 0% of the class. The filing explains that, on January 12, 2026, The Vanguard Group underwent an internal realignment and certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report about its stake in Korro Bio (KRRO)?
Does the filing identify any Vanguard subsidiary holdings in Korro Bio (KRRO)?
Who signed the Schedule 13G/A amendment for Vanguard regarding KRRO?
AI-generated analysis. How Rhea-AI works. Not financial advice.